Wockhardt has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.

Wockhardt’s bulk vaccine and fill-finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and an expert from CDL Kasauli to receive export NOC.

Wockhardt’s state-of-the-art automated manufacturing facilities in Aurangabad are dedicated to produce world class high quality injectable products.

Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19 based on the technology transfer from Gamaleya National Research Institute of Epidemiology and Microbiology.

Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V). A one-shot vaccination regimen of Sputnik Light provides for ease of administration and helps to increase efficacy and duration of other vaccines when used as a booster shot.

Clinical studies and the real-world data in many countries have demonstrated Sputnik Light is a safe and effective vaccine when used both on a standalone basis and as a booster.

A study in Argentina on heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino has demonstrated that each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on 14th day after administering the second dose as compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.